The effects of reducing worry in patients with persecutory delusions: finding out if worries can be reduced by brief cognitive therapy

Submission date 07/03/2011

Recruitment statusNo longer recruiting

Registration date 20/04/2011

Overall study status

Completed

Last Edited

Condition category

18/12/2017 Mental and Behavioural Disorders

[X]	Prospect	ively	regist	ered
-----	----------	-------	--------	------

[X] Protocol

[X] Results

Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Daniel Freeman

Contact details

Department of Psychiatry Oxford University Warneford Hospital Oxford United Kingdom OX3 7JX

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers 09/160/06

Study information

Scientific Title

The effects of reducing worry in patients with persecutory delusions: An explanatory randomised controlled trial

Acronym

Worry Intervention Trial (WIT)

Study objectives

- 1. A worry intervention will reduce levels of worry in individuals with persecutory delusions
- 2. A worry intervention will reduce persecutory delusions, especially levels of distress
- 3. The improvements will be maintained at follow-up

Ethics approval required

Old ethics approval format

Ethics approval(s)

NHS Research Ethics Service Oxford REC B, application ref 11/SC/0001 - approval pending as of 09/03/2011

Study design

Single-blind randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Other

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Persecutory delusions in the context of schizophrenia or related diagnosis

Interventions

- 1. Six sessions of CBT for worry over 2 months for patients randomised to intervention arm 2. This is in addition to their standard psychiatric care
- 3. The control condition is standard psychiatric care

Intervention Type

Other

Phase

Not Applicable

Primary outcome measure

- 1. Penn State Worry Questionnaire (PSWQ; Meyer et al, 1990)
- 2. Psychotic Symptoms Rating Scale Delusions (PSYRATS; Haddock et al, 1999)

Secondary outcome measures

- 1. Paranoid Thoughts Scale (Green et al, 2008)
- 2. Positive and Negative Symptom Scale (PANSS; Kay, 1991).
- 3. EQ-5D (Brooks et al, 2003)

Overall study start date

01/09/2011

Completion date

01/03/2014

Eligibility

Key inclusion criteria

- 1. A current persecutory delusion as defined by Freeman and Garety (2000); scoring at least 3 on the conviction scale of the PSYRATS (Haddock et al, 1999)
- 2. That the delusion has persisted for at least one month
- 3. A clinical diagnosis of schizophrenia, schizoaffective disorder or delusional disorder (i.e. diagnosis of non-affective psychosis (F2) in the International Classification of Diseases and Diagnostic and Statistical Manual IV)
- 4. A clinically significant level of worry, as indicated by scores above 44 on the Penn State Worry Questionnaire (see Startup and Erickson, 2006)
- 5. Aged between 18 and 65
- 6. Where major changes in medication are being made, entry to the study would not occur until at least a month after stabilisation of dosage

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

150

Key exclusion criteria

- 1. A primary diagnosis of alcohol or substance dependency
- 2. Organic syndrome or learning disability
- 3. A command of spoken English inadequate for engaging in therapy
- 4. Currently having individual cognitive behavioural therapy (CBT) (though previous CBT experience is not an exclusion)

Date of first enrolment

01/09/2011

Date of final enrolment

01/03/2014

Locations

Countries of recruitment

England

United Kingdom

Study participating centre Oxford University

Oxford United Kingdom OX3 7JX

Sponsor information

Organisation

The Efficacy and Mechanism Evaluation Programme (MRC/NIHR) (UK)

Sponsor details

NETSCC - Efficacy and Mechanism Evaluation Alpha House University of Southampton Science Park Southampton United Kingdom SO16 7NS

Sponsor type

Government

Website

http://www.eme.ac.uk

ROR

https://ror.org/0187kwz08

Funder(s)

Funder type

Government

Funder Name

National Institute for Health Research

Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	pilot study results	01/03/2010		Yes	No
Protocol article	protocol	21/11/2012		Yes	No
Results article	results	01/04/2015		Yes	No